ASMQ IN A FEW WORDS ASMQ, FIRST NEW MALARIA TREATMENT MADE IN LATIN AMERICA, FOR LATIN AMERICA AND SOUTH EAST ASIA • ASMQ = Artesunate + Mefloquine - first fixed dose of this combination and first ACT combination shown to be effective in the field • ASMQ is one of four first line ACT treatments recommended by WHO for uncomplicated falciparum malaria in Asia and Latin America • A New Fixed-Dose ACT Developed in Response to Patient Need and a Most Convenient Treatment o The 2-in-1 combination of ASMQ ensures that both drugs are taken together in correct proportions • Simple Regimen for Children and Adults - Easy to Use as 1-2-3 with One Daily Administration of 1 or 2 Tablets over 3 Days according to age • Packaging Adapted for Ease-of Use and with longest shelf life of any FDC for malaria - three-year shelf life • From the lab to the patient - First new malaria product and first new neglected diseases medicine to be produced by Farmanguinhos, (public pharmaceutical company which produced all the generic ARVs for the national HIV program) • First New Product for Neglected Diseases Developed and Now Registered in Brazil AN INNOVATIVE PARTNERSHIP TO DELIVER A PUBLIC GOOD • Public Good Available At Cost, Available Now in Brazil • ASMQ will be available in other countries in Latin America and Southeast Asia in 2008 and 2009 • Made Possible Through a Non-Profit Initiative Driven by Public Funds • Innovative Collaboration Between Brazil and Asia Within DNDi’s FACT Project Consortium • Principle of South-South technology tranfer agreed to by Brazil (Farmanguinhos) to India (Cipla) • ASMQ - A product developed, delivered and supported by public partners of the DNDi FACT Project, A Worldwide Collaboration to Address the Needs of Malaria Sufferers • Development cost for DNDi is 7.8 million Euros, funded by the EU, French, Spanish, Netherlands and UK government grants and MSF, with an important in-kind contributions from Farmanguinhos/Fiocruz and others. THE EVIDENCE FOR ASMQ IN TREATMENT OF MALARIA • Well-Established Use of the Non-Fixed Combination of AS and MQ • Combination of AS and MQ has been used in the field for 16 years - shown to be highly effective in multi-drug resistant areas • Approximately 230,000 cases of uncomplicated malaria in Latin America; 1.5 million cases in Southeast Asia • DNDi-supported study in Tanzania to examine possibility of use of ASMQ on continent of Africa with >300 million cases of uncomplicated malaria • International Quality Registration Dossier Supported By Published Data • Clinical evidence on use of ASMQ in Over 15,000 Patients in Southeast Asia • Preliminary results at 1 year of large intervention study by Brazilian Ministry of Health Malaria Control Program (ongoing in the Amazon Basin), in around 17,000 patients showed 70% drop in number of cases reported For further information call Samantha Bolton on +55 21 8253 2126 / +41 79 239, Sadia Kaenzig on: +41 79 819 99 71, Ann-Marie Sevcsik on: +41 79 814 9147 / +1 646 258 8131 - thanks! |
|
||||||
